<\/p>\n
Shoppers of ideas are increasingly turning to operator\u2011turned investors to spot the next wave of health tech. Kaakpema \u201cKP\u201d Yelpaala, now a venture partner at Heuristic Capital and leader of Yale\u2019s Future of Health Innovation Hub, explains why builders make better backers and which startups will matter most.<\/strong><\/p>\n Essential Takeaways<\/p>\n There\u2019s a different tone when someone who\u2019s shipped products joins the other side of the table; it\u2019s practical, a bit impatient, and quietly sympathetic. Yelpaala says his time as an operator taught him the messy, non\u2011linear work of building sustainable digital health ventures, which now informs how he evaluates deals. To some, deep tech is exotic , quantum computing or other cutting\u2011edge physics\u2011led breakthroughs , but in venture terms it\u2019s simply hard science with long horizons. For Yelpaala, health tech sits next to deep tech but is judged by a different metric: how fast and cleanly it can integrate with care delivery and regulation. Yelpaala\u2019s split role at Yale gives him a front\u2011row seat to academic inventors and students tackling population health problems. He\u2019s mentoring concepts that range from home\u2011based care models to longevity biomarkers and hardware\/software hybrids for remote diagnostics. Yelpaala thinks healthcare will increasingly lean on longevity science and biotechnology to personalise care at scale, but the real lever is payment reform. Value\u2011based care , aligning payment to outcomes , is what will reward tech that reduces costs and improves quality. One advantage of operator\u2011investors is their willingness to roll up sleeves. Yelpaala\u2019s background suggests he\u2019ll mentor teams on product ops, clinical integration and fundraising craft, not just introduce KPIs on a spreadsheet. It’s a small change that can make every startup’s journey more navigable , and every patient experience a bit better.<\/p>\n\n
Why founders make some of the best investors , and what that actually feels like<\/h2>\n
\nThat empathy matters. Founders often complain about VCs who seem to trade in buzzwords rather than lived experience. An investor who\u2019s been in the trenches tends to ask sharper questions about product\u2011market fit, clinical workflows and team stamina.
\nPractical tip: if you\u2019re pitching, expect operator\u2011investors to probe how you\u2019ll actually implement in real health settings, not just how clever the tech is.<\/p>\nWhat Heuristic means by \u201cdeep tech\u201d and \u201chealth tech\u201d , and why the distinction is useful<\/h2>\n
\nHeuristic hunts for AI\u2011forward companies but is cautious of shallow automation plays; they favour innovations that change outcomes or move care closer to the home.
\nPractical tip: founders should map their regulatory and reimbursement route early; investors are increasingly filtering for realistic translation pathways.<\/p>\nYale\u2019s innovation hub: a factory for early ideas in home care, longevity and remote diagnostics<\/h2>\n
\nUniversities often generate brilliant, raw ideas but lack the route to scale; hubs like Yale\u2019s focus on translation , getting prototypes into pilots and partnerships. For investors that creates a visible funnel of de\u2011risked, founder\u2011adjacent opportunities.
\nPractical tip: if you\u2019re an academic founder, seek partners who understand both publication metrics and market realities.<\/p>\nThe future of care: longevity, value\u2011based models and the pace question<\/h2>\n
\nThat said, he\u2019s realistic: transition timing is uncertain. Regulatory nudges and pilot programmes are pushing things forward, but founders must design products that survive in both fee\u2011for\u2011service and value\u2011oriented worlds.
\nPractical tip: build flexible business models and measure outcome signals investors care about , cost per patient, readmission rates, or time\u2011to\u2011diagnosis.<\/p>\nHow early investors can help founders beyond cheques<\/h2>\n
\nThat hands\u2011on approach often speeds the \u201cover\u2011the\u2011fence\u201d journey from university lab to seed stage, and it\u2019s why academic founders may prefer investors who teach as well as fund.
\nPractical tip: when choosing early investors, ask about mentoring bandwidth and who will open doors to pilots, payers or regulatory counsel.<\/p>\nSource Reference Map<\/h3>\n